Annual Congress Munich 2006

Saturday, 02.09.2006
Sunday, 03.09.2006
Monday, 04.09.2006
Tuesday, 05.09.2006
Wednesday, 06.09.2006

Citations should be made in the following way: Authors. Title. Eur Respir J 2006; 28: Suppl. 50, abstract number.

Material from 2006:

4395 Abstracts
610 Slide presentations
175 Webcasts
95 Handouts
175 Multimedia files

Material from 2006: Show

Lung cancer treatment

Oral Presentation
Chairs: R. Huber (Munich, Germany), P. Zatloukal (Prague, Czech Republic)

Download all media

Changes in the patterns of care for lung cancer from 1996 to 2001 in an Australian region N. Esmaili, M. Hensley, K. Clover, S. Ackland (Newcastle, Australia)
Impact of surgery on quality of life in bronchogenic carcinoma operated patients N. Castejón, S. Asensio, L. Hernández, J. Cerezal, S. Romero (Alicante, Spain)
Systematic review of the effect of chemotherapy on quality of life (QoL) and symptom control in patients with non-small cell lung cancer (NSCLC) K. E. Pat, C. A. Dooms, J. F. Vansteenkiste (Leuven, Belgium)
Phase II open-label study to investigate efficacy and safety of PTK787/ZK 222584 (PTK/ZK) orally administered once daily at 1250 mg as second-line monotherapy in patients (pts) with stage IIIB/IV non-small-cell lung cancer (NSCLC) T. C. Gauler, B. Fischer, J. C. Soria, V. Gounant, F. Griesinger, H. Krissel, D. Laurent, W. Eberhardt (Essen, Mainz, Goettingen, Berlin, Germany; Villejuif, Paris, France)
*Indcution chemotherapy and radiotherapy vs.* induction and simultaneous radiochemotherapy in inoperable stage III NSCLC. Update on BROCAT study CTRT 99/97** R. M. Huber, M. Flentje, G. Beckmann, A. Borgmeier, M. Schmidt, F. Schmuck, T. Schuster, K. Ulm (Munich, Wuerzburg, Germany)
A randomised phase III trial by the European lung cancer working party comparing sequential administration of cisplatin-based chemotherapy followed by a taxan and a cisplatin-based standard chemotherapy, with the use of taxan as salvage treatment A. P. Meert, J. J. Lafitte, J. Lecomte, C. Alexopoulos, O. Van Cutsem, V. Giner, A. Efremidis, M. C. Berchier, A. Scherpereel, V. Ninane, M. Paesmans, T. Berghmans, J. P. Sculier (Belgium; France; Greece; Spain)
Ras peptide-specific vaccination in patients with non-small cell lung cancer (NSCLC) S. Korn, R. G. Meyer, P. Micke, C. Huber, T. Wölfel, R. Buhl (Mainz, Germany; Uppsala, Sweden)
A prospective phase II study of gefitinib for chemo-naïve patients with advanced non-small cell lung cancer with epidermal growth factor receptor gene mutations N. Morikawa, A. Inoue, T. Fukuhara, M. Maemondo, S. Sugawara, O. Ishimoto, Y. Saijo, T. Nukiwa (Sendai, Miyagi, Sendai, Japan)